They have also verified that treatment with anti-TIM-3 concurrently with anti-PD-L1 and RT leads to significant tumor growth delay, enhanced T-cell cytotoxicity, decreased proportion of Tregs, and improved survival in HNSCC. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.